Wall St. Icon: “If you wait on this, it will already be too late”

If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.

Neena Patil Biography and Net Worth

Insider of Jazz Pharmaceuticals

Neena M. Patil has served as Jazz’s chief legal officer since July 2019. Ms. Patil has been practicing law for 20 years and oversees all legal, corporate affairs and government relations matters for the Company. Ms. Patil is recognized for her track record of execution, including in connection with more than a dozen commercial launches and for her successful resolution of complex litigation, compliance investigations, and other corporate reputation matters. Ms. Patil has worked for several global biopharmaceutical companies over her career and currently serves on the board of Teleflex Inc., where she is a member of the Nominating and Corporate Governance Committee. She also serves on the board of mothers2mothers, a global women’s health organization operating in sub-Saharan Africa.

From September 2018 to July 2019, Ms. Patil served as senior vice president, general counsel and corporate secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as vice president for legal affairs and associate general counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Ms. Patil received a B.A. from Georgetown University and a J.D. and Master of Health Services Administration from the University of Michigan.

What is Neena M. Patil's net worth?: The estimated net worth of Neena M. Patil is at least $4.09 million as of November 8th, 2024. Ms. Patil owns 33,048 shares of Jazz Pharmaceuticals stock worth more than $4,089,029 as of December 24th. This net worth evaluation does not reflect any other investments that Ms. Patil may own. Additionally, Ms. Patil receives a salary of $1,010,000.00 as Insider at Jazz Pharmaceuticals. Learn More about Neena M. Patil's net worth.
How old is Neena M. Patil?: Ms. Patil is currently 49 years old. There are 7 older executives and no younger executives at Jazz Pharmaceuticals. The oldest executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who is 60 years old. Learn More on Neena M. Patil's age.
What is Neena M. Patil's salary?: As the Insider of Jazz Pharmaceuticals plc, Ms. Patil earns $1,010,000.00 per year. There are 3 executives that earn more than Ms. Patil. The highest earning executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who commands a salary of $2,440,000.00 per year. Learn More on Neena M. Patil's salary.
How do I contact Neena M. Patil?: The corporate mailing address for Ms. Patil and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Neena M. Patil's contact information.
Has Neena M. Patil been buying or selling shares of Jazz Pharmaceuticals?: In the last ninety days, Neena M. Patil has sold $456,617.00 of Jazz Pharmaceuticals stock. Most recently, Neena M. Patil sold 3,700 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a transaction totalling $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at $4,078,453.68. Learn More on Neena M. Patil's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Neena M. Patil Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2024	Sell	3,700	$123.41	$456,617.00	33,048
5/3/2024	Sell	5,000	$109.65	$548,250.00	36,629
9/1/2023	Sell	1,500	$144.25	$216,375.00	29,186
8/15/2023	Sell	750	$139.59	$104,692.50	30,686
6/1/2023	Sell	1,600	$127.98	$204,768.00	32,826
6/6/2022	Sell	1,000	$152.15	$152,150.00	31,600
5/6/2022	Sell	296	$153.92	$45,560.32	32,677

Neena M. Patil Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $123.73

$121.19

$124.61

50 Day Range

MA: $119.15

$108.05

$127.74

2 Week Range

Now: $123.73

$99.06

$134.17

Volume

187,949 shs

Average Volume

672,842 shs

Market Capitalization

$7.48 billion

P/E Ratio

17.43

Dividend Yield

N/A

Beta

0.57

Wall St. Icon: “If you wait on this, it will already be too late”

From InvestorPlace | Ad

If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.

Go here now to see my urgent warning

Neena Patil Biography and Net Worth

What is Neena M. Patil's net worth?

How old is Neena M. Patil?

What is Neena M. Patil's salary?

How do I contact Neena M. Patil?

Has Neena M. Patil been buying or selling shares of Jazz Pharmaceuticals?

Who are Jazz Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Jazz Pharmaceuticals?